U.S. flag An official website of the United States government
  1. Home
  2. For Industry
  3. FDA User Fee Programs
  4. Prescription Drug User Fee Amendments
  5. Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs
  1. Prescription Drug User Fee Amendments

Program for Enhanced Review Transparency and Communication for NME NDAs and Original BLAs

As part of its commitments in PDUFA V, FDA has established a new review program (“the Program”) to promote greater transparency and increased communication between the FDA review team and the applicant on the most innovative products reviewed by the agency. The Program applies to all new molecular entity new drug applications (NME NDAs) and original biologics license applications (BLAs) that are received from October 1, 2012, through September 30, 2017.

The goals of the Program are to increase the efficiency and effectiveness of the first review cycle and decrease the number of review cycles necessary for approval so that patients have timely access to safe, effective, and high quality new drugs and biologics

The key features of the Program include:

  • new opportunities for communication between applicants and the FDA review team during the agency’s review of the application

  • additional review clock time for the agency to meet with applicants during review as well as to address review activities that occur late in the review cycle for these highly complex applications

  • an interim and final assessment that will evaluate whether the parameters of the Program have achieved the intended goals.

This page contains information relevant to the assessments as well as other communications related to the Program. Additional details about the Program can be found in Section II of the PDUFA V Commitment Letter (PDF - 240KB).

Assessment of the Program

Final Assessment Public Meeting on March 27, 2017

Interim Assessment Public Meeting on May 20, 2015


Back to Top